#AANAM – Epidiolex Reduced Seizures in Dravet Youngsters, Study Finds

GW PharmaceuticalsEpidiolex, the first plant-derived cannabidiol (CBD) medication to be approved by the U.S. Food and Drug Administration (FDA), reduces the frequency of epileptic seizures when used as an add-on therapy in children with Dravet syndrome, a Phase 3 clinical trial shows.

That finding was presented in a poster titled, “Cannabidiol (CBD) Significantly Reduces Convulsive Seizure Frequency in Children and Adolescents with Dravet Syndrome: Results of a Dose-ranging, Multi-center, Randomized, Placebo-controlled Trial (GWPCARE2),” at the American Academy of Neurology (AAN) Annual Meeting in Philadelphia.

Dravet syndrome is a rare genetic disorder characterized by severe, recurrent seizures that fail to respond to treatment with conventional anti-epileptic drugs.

Marketed by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals, Epidiolex is a purified liquid formulation of plant-derived cannabis that is supplied as a 100 mg/mL strawberry-flavored oral solution in a sesame oil base.

Previous clinical trials

... read more at: https://dravetsyndromenews.com/2019/05/10/epidiolex-reduces-seizures-children-dravet-children/